Navigation Links
Provent® Sleep Apnea Therapy Now Available in India
Date:7/19/2011

BELMONT, Calif. and HYDERABAD, India, July 20, 2011 /PRNewswire/ -- Ventus Medical is pleased to announce the Indian launch of its proprietary Provent® Sleep Apnea Therapy, an innovative, non-invasive treatment for obstructive sleep apnea (OSA). Orbees Business Solutions Pvt. Ltd. will be the strategic market developer of Provent Therapy in India.

(Logo:  http://photos.prnewswire.com/prnh/20110209/SF45785-a)

(Logo:  http://photos.prnewswire.com/prnh/20110209/SF45785-b)

"India has a very high prevalence of obstructive sleep apnea. Roughly 20% of urban Indian males suffer from OSA," said Rajiv Doshi, M.D., Chief Scientific Officer of Ventus Medical and inventor of the Provent technology. Dr. Doshi is faculty at Stanford University and serves as Executive Director (US) of the Stanford India Biodesign program, a Government of India funded collaboration between Stanford University and the All India Institute of Medical Sciences (AIIMS) and the Indian Institute of Technology Delhi. "With a very large patient need, we believe that Provent Therapy provides a reliable and clinically-proven solution to treat the millions of people in India with OSA."

In patients with OSA the airway collapses during sleep when the muscles that hold it open relax. People with this disorder stop breathing during the night---in some cases hundreds of times each night---usually for periods of ten seconds or longer. Sleep apnea can lead to fatigue, early morning headaches, irritability, lack of concentration, and contributes to depression, learning and memory difficulties, and sexual dysfunction. Importantly, many recent studies have shown that OSA is associated with high blood pressure, irregular heartbeat, heart attack, stroke and diabetes.

"Many people in India go undiagnosed and very few receive treatment due to the many complexities associated with existing treatment options, such as CPAP (continuous positive airway pressure),"  said Dr. Manvir Bhatia, Director of Neurology and Sleep Centre, New Delhi. "There is an increasing need for OSA treatments that do not rely on power and are highly portable – Provent Therapy represents one such alternative for our patients and is likely to become a first line of therapy."

Ensuring ready access and good patient support for Provent Therapy are important considerations when serving the Indian sleep apnea patient.  "As we expand Provent Therapy's international presence, we believe India provides an unparalleled opportunity for Ventus," commented Peter Wyles, President and Chief Executive Officer of Ventus Medical. "We've established a business relationship with a strategic market developer in India to help us launch and develop the right distribution network across this large market. We believe that the partnership with Orbees will allow us to optimize the business model for this emerging, complex market."

"We are proud to help Ventus introduce this game-changing therapy to sleep medicine experts and their patients in India," added Dr. Anurag Mairal, Executive Vice President of Orbees. "Our first-of-its-kind market research, that surveyed hundreds of potential patients and physicians, has proven to us that the market is significantly underserved with less than 0.1% of the Indian OSA population diagnosed, and less than 25% of the OSA diagnosed patients receiving treatment."

About Provent® Sleep Apnea Therapy

Provent® Therapy is an FDA approved and CE Marked medical device indicated for the treatment of obstructive sleep apnea (OSA). The device has been shown to be clinically effective in a series of peer reviewed studies.  It is an easy to use, non-invasive and disposable treatment that works across mild, moderate, and severe OSA. Provent Therapy utilizes nasal expiratory positive airway pressure (EPAP) to keep a patient's airway open during sleep and has been clinically proven in numerous studies to reduce sleep apnea.  It incorporates a novel MicroValve design that is placed over the nostrils and secured with hypoallergenic adhesive. During inhalation, the valve opens allowing nearly unobstructed airflow, and during exhalation, the valve closes, limiting airflow through small openings, which increases expiratory pressure and keeps the airway open, preventing disruption in breathing. For more information, please visit www.proventtherapy.com.

About Orbees Business Solutions Pvt. Ltd.

Orbees Business Solutions Pvt. Ltd. (Orbees) provides leading edge marketing and sales solutions that include consulting and market development services in India. The company has an innovative approach to developing emerging medical device markets that centers around physician and patient education. The company's U.S. counterpart, Orbees Medical, has quickly built a reputation in the medical device industry for its clinical depth and understanding of market trends.

About Ventus Medical

Ventus Medical is a privately-held medical device company dedicated to providing non-invasive medical solutions for people with sleep-disordered breathing. Based on its innovative MicroValve technology and patented designs, Ventus has developed a unique line of clinically-proven medical devices to address the continuum of sleep disorders from severe obstructive sleep apnea (OSA) to mild snoring. Ventus Medical devices work by creating expiratory positive airway pressure (EPAP) to effectively treat the underlying conditions.  The company markets Provent® Therapy, a discreet, easy-to-use nasal device, for the treatment of obstructive sleep apnea in the United States, Hong Kong and India, and is developing an over-the-counter device for snoring.


'/>"/>
SOURCE Ventus Medical
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Multiple Presentations Confirm Clinical Efficacy and High Rate of Patient Compliance Using Provent® Sleep Apnea Therapy to Treat Obstructive Sleep Apnea
2. Publication in SLEEP Journal Demonstrates Positive Results of Large Multi-Center Clinical Trial for Provent® Sleep Apnea Therapy
3. Ventus Medical Receives CE Mark for Provent® Sleep Apnea Therapy
4. Study Confirms Provent® Therapy Effectively Treats Sleep Apnea Patients Who Are Non-Compliant with CPAP Therapy
5. Omeros Unlocks Orphan GPCRs Linked to Leukemia and Sleep Disorders
6. Sleeping Bags Specialist Stocks New Care Plus Tick Test
7. Acurests Custom CPAP Mask Now Available for Sleep Apnea Sufferers in the U.S.
8. Ajinomoto Co., Inc. Harnesses Amino Acid Power to Improve Sleep
9. Global Sleep Apnea Diagnostic And Therapeutic Devices Industry
10. Retrospective Analysis Explores LYSTEDA®s Ability to Reduce Sleep Interruptions in Women With Cyclic Heavy Menstrual Bleeding
11. Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
Breaking Medicine News(10 mins):